Editas Medicine, Inc. (EDIT)
2.90
+0.06
(+2.11%)
USD |
NASDAQ |
Oct 09, 16:00
2.87
-0.03
(-1.03%)
After-Hours: 20:00
Editas Medicine Free Cash Flow : -120.55M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -120.55M |
| March 31, 2026 | -141.09M |
| December 31, 2025 | -165.85M |
| September 30, 2025 | -180.70M |
| June 30, 2025 | -204.94M |
| March 31, 2025 | -215.28M |
| December 31, 2024 | -219.11M |
| September 30, 2024 | -191.36M |
| June 30, 2024 | -171.54M |
| March 31, 2024 | -151.03M |
| December 31, 2023 | -136.90M |
| September 30, 2023 | -156.25M |
| June 30, 2023 | -169.17M |
| March 31, 2023 | -167.60M |
| December 31, 2022 | -181.47M |
| September 30, 2022 | -176.00M |
| June 30, 2022 | -170.51M |
| March 31, 2022 | -173.69M |
| December 31, 2021 | -171.78M |
| September 30, 2021 | -175.83M |
| June 30, 2021 | -189.29M |
| March 31, 2021 | -180.33M |
| Date | Value |
|---|---|
| December 31, 2020 | -187.00M |
| September 30, 2020 | -106.20M |
| June 30, 2020 | -78.73M |
| March 31, 2020 | -73.35M |
| December 31, 2019 | -46.84M |
| September 30, 2019 | -86.26M |
| June 30, 2019 | -65.91M |
| March 31, 2019 | -56.71M |
| December 31, 2018 | -50.46M |
| September 30, 2018 | -75.73M |
| June 30, 2018 | -95.68M |
| March 31, 2018 | -104.08M |
| December 31, 2017 | -11.48M |
| September 30, 2017 | -0.151M |
| June 30, 2017 | 10.82M |
| March 31, 2017 | 26.29M |
| December 31, 2016 | -53.42M |
| September 30, 2016 | -47.76M |
| June 30, 2016 | -42.13M |
| March 31, 2016 | -11.16M |
| December 31, 2015 | -6.834M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Recursion Pharmaceuticals, Inc. | -354.26M |
| Geron Corp. | -114.76M |
| Halozyme Therapeutics, Inc. | 806.22M |
| Novavax, Inc. | -43.02M |
| AVITA Medical, Inc. | -25.21M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -29.57M |
| Cash from Investing (Quarterly) | -29.80M |
| Cash from Financing (Quarterly) | 117.54M |
| Free Cash Flow Per Share (Quarterly) | -0.2487 |
| Free Cash Flow to Equity (Quarterly) | -28.95M |
| Free Cash Flow to Firm (Quarterly) | -28.61M |
| Free Cash Flow Yield | -41.10% |